• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

乳腺癌寡转移和寡进展的诊治：现状与未来方向。

Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.

机构信息

Department of Radiation Oncology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA.

出版信息

Curr Oncol Rep. 2024 Jun;26(6):647-664. doi: 10.1007/s11912-024-01529-2. Epub 2024 Apr 23.

DOI:10.1007/s11912-024-01529-2
PMID:38652425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11168988/
Abstract

PURPOSE

We examine the potential for curative approaches among metastatic breast cancer (MBC) patients by exploring the recent literature on local ablative therapies like surgery and stereotactic body radiation therapy (SBRT) in patients with oligometastatic (OM) breast cancer. We also cover therapies for MBC patients with oligoprogressive (OP) disease.

KEY FINDINGS

Surgery and SBRT have been studied for OM and OP breast cancer, mainly in retrospective or non-randomized trials. While many studies demonstrated favorable results, a cooperative study and single-institution trial found no support for surgery/SBRT in OM and OP cases, respectively.

CONCLUSION

While there is interest in applying local therapies to OM and OP breast cancer, the current randomized data does not back the routine use of surgery or SBRT, particularly when considering the potential for treatment-related toxicities. Future research should refine patient selection through advanced imaging and possibly explore these therapies specifically in patients with hormone receptor-positive or HER2-positive disease.

摘要

目的

通过探讨寡转移（OM）乳腺癌患者手术和立体定向体部放疗（SBRT）等局部消融治疗的最新文献，研究转移性乳腺癌（MBC）患者的潜在治愈方法。我们还涵盖了寡进展（OP）疾病 MBC 患者的治疗方法。

主要发现

手术和 SBRT 已在 OM 和 OP 乳腺癌患者中进行了研究，主要是在回顾性或非随机试验中。虽然许多研究显示出良好的结果，但一项合作研究和单机构试验分别发现 OM 和 OP 病例中手术/SBRT 没有支持。

结论

虽然人们有兴趣将局部治疗应用于 OM 和 OP 乳腺癌，但目前的随机数据并不支持常规使用手术或 SBRT，特别是当考虑到治疗相关毒性的潜在风险时。未来的研究应通过先进的影像学来完善患者选择，并可能专门针对激素受体阳性或 HER2 阳性疾病的患者探索这些治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4706/11168988/1fe9548369ce/11912_2024_1529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4706/11168988/1694ee56df2b/11912_2024_1529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4706/11168988/147f0eb18d27/11912_2024_1529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4706/11168988/1fe9548369ce/11912_2024_1529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4706/11168988/1694ee56df2b/11912_2024_1529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4706/11168988/147f0eb18d27/11912_2024_1529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4706/11168988/1fe9548369ce/11912_2024_1529_Fig3_HTML.jpg

相似文献

1
Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.乳腺癌寡转移和寡进展的诊治：现状与未来方向。
Curr Oncol Rep. 2024 Jun;26(6):647-664. doi: 10.1007/s11912-024-01529-2. Epub 2024 Apr 23.
2
Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.立体定向消融体部放射治疗颅外寡转移和寡进展性乳腺癌的治疗结果：单中心经验的成熟结果。
Clin Oncol (R Coll Radiol). 2024 Jun;36(6):362-369. doi: 10.1016/j.clon.2024.03.012. Epub 2024 Mar 19.
3
Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression.比较寡转移或寡进展患者接受立体定向体部放疗的生存和预后因素。
Radiother Oncol. 2018 Jun;127(3):493-500. doi: 10.1016/j.radonc.2018.04.022. Epub 2018 May 4.
4
The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review.立体定向体部放疗（SBRT）治疗寡进展性乳腺癌的有效性和安全性：系统评价。
Curr Oncol. 2023 Jul 21;30(7):6976-6985. doi: 10.3390/curroncol30070505.
5
Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.立体定向体部放疗（SBRT）治疗寡转移/寡进展性肾上腺转移瘤患者：单中心研究中的结果和毒性特征。
Cancer Treat Res Commun. 2021;29:100481. doi: 10.1016/j.ctarc.2021.100481. Epub 2021 Oct 21.
6
[Treatment of oligometastatic or oligoprogression cancer].[寡转移或寡进展性癌症的治疗]
Cancer Radiother. 2019 Oct;23(6-7):482-485. doi: 10.1016/j.canrad.2019.07.143. Epub 2019 Sep 5.
7
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.立体定向消融放疗与全身治疗在肺癌颅外寡转移、寡复发、寡残留和寡进展中的应用。
BMC Cancer. 2019 Dec 19;19(1):1237. doi: 10.1186/s12885-019-6449-8.
8
Local treatment in oligometastasis from breast cancer: an overview.局部治疗寡转移乳腺癌：综述。
Clin Transl Oncol. 2023 Oct;25(10):2861-2867. doi: 10.1007/s12094-023-03170-0. Epub 2023 Apr 27.
9
Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.寡转移/寡进展性非小细胞肺癌患者的立体定向放疗和分割立体定向放疗：198 例“根治性”治疗患者的多机构系列研究结果。
Lung Cancer. 2020 Mar;141:1-8. doi: 10.1016/j.lungcan.2019.12.019. Epub 2020 Jan 3.
10
Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.寡转移乳腺癌：我们现在在哪里，未来在哪里？——一篇叙述性综述。
Ann Palliat Med. 2021 May;10(5):5954-5968. doi: 10.21037/apm-20-1128. Epub 2020 Sep 10.

引用本文的文献

1
Characteristics of Oligo-Recurrence and Treatment Selection in Non-Small Cell Lung Cancer.非小细胞肺癌寡复发性的特征及治疗选择
Cancers (Basel). 2025 Jul 10;17(14):2293. doi: 10.3390/cancers17142293.
2
Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer.转移导向放射治疗对延长寡进展性转移性乳腺癌患者全身治疗的疗效
Cancers (Basel). 2025 Jun 26;17(13):2153. doi: 10.3390/cancers17132153.
3
Unexpected contralateral axillary lymph node metastasis without ipsilateral involvement in triple-negative breast cancer: A case report and review of literature.

本文引用的文献

1
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.乳腺癌的分子残留疾病：检测与治疗干预。
Clin Cancer Res. 2023 Nov 14;29(22):4540-4548. doi: 10.1158/1078-0432.CCR-23-0757.
2
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.高危早期 HER2 阴性乳腺癌患者接受新辅助化疗时循环肿瘤 DNA 的临床意义和生物学特性。
Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4.
3
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
三阴性乳腺癌中意外出现的对侧腋窝淋巴结转移而无同侧受累：一例报告及文献复习
World J Clin Cases. 2025 Jun 26;13(18):103571. doi: 10.12998/wjcc.v13.i18.103571.
4
The heterogeneity in oligoprogression and stereotactic body radiation therapy.寡进展与立体定向体部放射治疗中的异质性。
Transl Cancer Res. 2025 Jan 31;14(1):1-6. doi: 10.21037/tcr-24-1737. Epub 2025 Jan 21.
5
Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer.HER2靶向抗体药物偶联物在乳腺癌患者治疗策略中的影响。
Heliyon. 2025 Jan 3;11(3):e41590. doi: 10.1016/j.heliyon.2024.e41590. eCollection 2025 Feb 15.
c-TRAK TN 试验结果：一项利用 ctDNA 突变追踪来检测中高危早期三阴性乳腺癌患者分子残留疾病并触发干预的临床试验。
Ann Oncol. 2023 Feb;34(2):200-211. doi: 10.1016/j.annonc.2022.11.005. Epub 2022 Nov 22.
4
Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial.立体定向体部放疗治疗乳腺癌寡转移肺及肝：一项前瞻性非随机Ⅱ期试验的毒性数据。
Curr Oncol. 2022 Oct 17;29(10):7858-7867. doi: 10.3390/curroncol29100621.
5
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.立体定向消融放疗治疗多达 5 个寡转移灶的癌症患者：非随机 2 期 SABR-5 临床试验的主要毒性效应结果。
JAMA Oncol. 2022 Nov 1;8(11):1644-1650. doi: 10.1001/jamaoncol.2022.4394.
6
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials.寡进展性疾病的局部治疗：前瞻性试验的系统评价。
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):676-683. doi: 10.1016/j.ijrobp.2022.08.027. Epub 2022 Aug 13.
7
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
8
The Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients With Oligometastatic Disease at 12 Months Post Stereotactic Body Radiation Therapy.立体定向体部放疗后12个月时疾病进展对寡转移疾病患者健康相关生活质量结局的影响
Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):989-999. doi: 10.1016/j.ijrobp.2022.07.012. Epub 2022 Jul 28.
9
Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study.颅外寡转移患者接受立体定向体部放疗的条件生存：国际联合会研究。
Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):902-909. doi: 10.1016/j.ijrobp.2022.06.073. Epub 2022 Jun 23.
10
Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND.寡转移实体瘤的确定性局部巩固治疗：随机篮子试验EXTEND导入阶段的结果
Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):910-918. doi: 10.1016/j.ijrobp.2022.05.023. Epub 2022 Jun 9.